Development code · Small Molecule
ACP-204
ACP-204 is a development code for Remlifanserin, developed by ACADIA Pharmaceuticals Inc..
- Status
- Phase 3 for Alzheimer's disease psychosis
- Mechanism
- 5-HT2A Inverse agonist
- Developer
- ACADIA Pharmaceuticals Inc.
Programs
- Remlifanserin for Alzheimer's disease psychosisPhase 3Active
- Remlifanserin for Lewy body dementia psychosisPhase 2Recruiting
Also known as
- ACP 204
- remlifanserin
- 2289704-13-6
- 3-[(4-cyclopropyloxyphenyl)methyl]-1-[(2,4-difluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)urea